Clinical Trial

New research provides the strongest human evidence that sleep actively clears toxic proteins linked to Alzheimer's, opening a new frontier for prevention.

With drug pipelines facing staggering failure rates, HKeyBio's new preclinical strategy aims to de-risk R&D and accelerate effective new treatments.

Roche's CT-388 posts impressive Phase II results, positioning it as a powerful new rival to Zepbound and Wegovy in the booming obesity drug market.

A new study reveals albumin, the most abundant protein in blood, is a powerful weapon against mucormycosis, offering new hope for treating this fatal infection.

New study shows oral weight loss drug QSYMIA, paired with digital tech, delivers major results, offering a cheaper alternative to pricey injectables.

A new COVID-19 drug targets patients who can't take Paxlovid, while a once-a-month pill could revolutionize how we prevent seasonal influenza.

Neurocrine Biosciences begins a Phase 2 trial for a new tardive dyskinesia drug, aiming to build on its market dominance and offer new hope for patients.

A first-in-class oral therapy targeting cellular metabolism has entered patient trials, offering new hope for a disease-modifying treatment for eczema.

A new external bioengineered liver has passed a crucial safety trial, offering a potential lifeline for patients with acute liver failure.

Privo Technologies reports its PRV211 patch was well-tolerated in a key trial, offering a new, localized approach to preventing oral cancer recurrence.

A major clinical trial setback for a promising liver disease drug leaves patients waiting and puts Bausch Health's future strategy under scrutiny.

New 24-month data suggests a novel drug could improve kidney function and reduce side effects for transplant patients, challenging a decades-old standard.

A study of Earth's 83-million-year-old past reveals an orbital wobble that can trigger rapid wet-dry cycles, a pattern that could return in a warmer world.

Swedish biotech innovator Hansa Biopharma wins a top award for its life-saving transplant tech, facing a pivotal year with FDA review on the horizon.

Ski champion Lindsey Vonn leverages her Olympic comeback to partner with biopharma firm Invivyd, aiming to educate Americans on antibody-based disease prevention.

Resalis Therapeutics hires a key leader from a Novo Nordisk acquisition to steer its novel RNA therapy, which aims for fat loss without muscle waste.

With $35.1M in new funding, Infinitopes is launching a human trial for its AI-designed vaccine aimed at preventing oesophageal cancer recurrence.

A new strategic alliance aims to overcome manufacturing hurdles and accelerate the delivery of potentially life-changing gene therapies for genetic blindness.

Ascletis Pharma unveils ASC37, a next-gen, once-monthly obesity drug claiming superior potency and convenience, challenging giants like Eli Lilly.

Corvus Pharmaceuticals is set to unveil pivotal early data for its novel eczema drug, soquelitinib, a moment analysts call a critical milestone.